Non-thyroid illness (NTI) is a condition in which the hypothalamic-pituitary-thyroid system and thyroid hormone metabolism are abnormal due to non-thyroidal diseases. Although NTI has been reported to occur in hyperglycemic emergencies in children, there have been few studies in adult cases. In this study, we examined adult patients with hyperglycemia regarding the frequency of NTI and its triggers. Adult diabetic patients who were hospitalized for diabetic ketosis (DK), diabetic ketoacidosis (DKA), or hyperglycemic hyperosmolarity syndrome (HHS) were included in the study. Compared with the DK group, the DKA and HHS groups had higher admission blood glucose, Anion Gap, serum osmolality, creatinine, and urea nitrogen, and lower pH and eGFR. The frequency of NTI in the DKA, HHS, and DK groups was 80%, 70%, and 50%, respectively, and thyroid stimulating hormone (TSH) and free thyroxine 3 (FT3) were significantly improved after treatment for hyperglycemia. Multiple regression analysis showed a significant correlation between the decrease in FT3 level and 3-hydroxybutyrate and albumin. Acute metabolic failure associated with hyperglycemia tends to be associated with a high rate of NTI and low FT3 levels at the start of treatment. The data in this study clearly shows that transient NTI is frequently observed in subjects with acute metabolic disorders such as DKA, HHS and DK. In addition, we should bear in mind that thyroid hormone replacement therapy is not necessary in subjects with NTI due to DKA, HHS and DK, especially when overt symptoms of hypothyroidism are not observed.

Keywords: diabetic ketosis, diabetic ketoacidosis, hyperglycemic hyperosmolarity syndrome, non-thyroidal illness, thyroid function

INTRODUCTION

Non-thyroid illness (NTI) is a condition in which the hypothalamic-pituitary-thyroid system and thyroid hormone metabolism are abnormal due to non-thyroidal diseases, and it is an adaptive response to reduce catabolism for biological defense in severe diseases (1). In non-thyroidal diseases, low T3 syndrome is the most common type, and severe infections such as sepsis can lead to insufficient secretion of thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone.
(TSH) due to inflammatory cytokines (2, 3). The mechanism of thyroid hormone depletion in NTI is that corticosteroids, inflammatory cytokines, and other factors reduce the 5'-deiodination response and impair the conversion of T4 to T3. It has been suggested that decreased TRH secretion due to decreased leptin and decreased TSH secretion due to inflammatory cytokines are involved in hypothyroidism in subjects with NTI (4).

Diabetes mellitus is a disease characterized by hyperglycemia due to inadequate insulin secretion and/or sensitivity. Diabetes cases with HbA1c >12% show a decrease in serum T3 concentration and a decrease or normal range of TSH (5). There are reports showing that serum T3 concentration is correlated with the management of diabetes (6). Factors such as dehydration, fasting, and excessive consumption of soft drinks can lead to metabolic disorders such as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), and diabetic ketosis (DK). A study reported by Shao et al. showed that pediatric patients with DKA and DK had abnormal thyroid function and that serum FT3 levels were correlated with β-hydroxybutyrate and bicarbonate ions (7). Although it has been reported that DKA and DK are involved in the pathogenesis of NTI in pediatric cases, there has been only a few case reports of HHS complicated by NTI or systemic inflammatory response syndrome (SIRS) in adult cases. Although there have been case reports of HHS complicated by NTI (8), no study has examined the impact of hyperglycemia-related metabolic dysfunction on thyroid dysfunction in adults. In the present study, we investigated the effects of DKA, HHS and DK on thyroid function.

MATERIALS AND METHODS

Study Subject

We performed this study with hospitalized patients retrospectively in our institution from April 1st in 2016 to June 30th in 2021 at the Department of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan. The study protocol including the Opt-out informed consent was approved by Institutional Review Board of Kawasaki Medical School (No. 5375-00). And the study was conducted in accordance with the Declaration of Helsinki. Since this study was retrospective, instead of obtaining informed consent from each patient, we provided public information about the study via the hospital homepage.

The criteria for diagnosing DKA, HHS, and DK were based on the criteria posted by the Japanese Diabetes Association. DKA was defined as pH less than 7.30, AnionGap greater than 12.0, and increased ketone bodies; HHS was defined as blood glucose level greater than 600 mg/dL and serum osmolality greater than 320 mOsm/kg; DK was defined as a diagnosis of diabetes mellitus and a state of ketosis that did not lead to acidosis. The definition of NTI in this study was as follows: thyroid hormone levels deviated from institutional reference values and were not accompanied by an elevated TSH. In addition, only cases in which other thyroid diseases could be excluded by measurement of thyroid-related autoantibodies and thyroid ultrasonography were included in the analysis.

We initially selected 56 patients who were ≥ 20 years old and were hospitalized in our institution for management of DKA, HHS or DK and whose thyroid hormones were measured. All patients admitted for the management of DKA, HHS or DK were included in the study. Patients with autoimmune thyroid disease, using thyroid medication or corticosteroids were also excluded from the analysis (4 patients). Finally, 52 patients were included: 20 patients in the DKA group, 10 patients in the HHS group, and 22 patients in the DK group.

Methods

On admission, diabetes- and thyroid-related parameters, arterial blood gas, liver function, renal function, blood pressure, body weight and body mass index (BMI) were assessed. During hospitalization, all patients were treated with intensive insulin therapy. Thyroid-associated antibodies (TRAb, TSAb, anti-TPO and anti-Tg antibodies) were measured and thyroid ultrasonography was performed in patients with abnormal thyroid hormone levels on admission. Thyroid hormone levels were retested when ketosis was improved to normal range or at discharge.

Statistical Analysis

The clinical characteristics of the subjects used in the analysis were age, laboratory findings on admission, and thyroid-related parameters at discharge. Group differences in each index among the DKA, HHS and DK groups were analyzed using the Tukey Kramer method and unpaired t tests. Changes in thyroid-related parameters before and after treatment were analyzed using the corresponding t-test. Multivariate linear regression analysis was used to test for factors contributing to thyroid-related parameters. Statistical software was Excel Statistics for Mac version 16.54 (Social Research Information Co., Ltd., Tokyo) and JMP version 16.0.1 (SAS Institute Inc.).

RESULTS

Clinical Characteristics

The clinical characteristics of the patients in this study are shown in Table 1. HbA1c (National Glycohemoglobin Standardization Program [NGSP]), 12.1 ± 3.8%, 12.4 ± 3.1% and 12.7 ± 2.5%; glycoalbumin: 42.5 ± 11.4%, 41.8 ± 11.8% and 36.6 ± 12.6% in DKA, HHS and DK group, respectively, suggesting the presence of marked hyperglycemia in all groups. There was no difference in HbA1c and glycoalbumin levels among the three groups. Total ketone bodies were 4660.1 ± 4027.3 μmol/L in DK group and 10115.4 ± 5157.3 μmol/L in DKA group (p<0.005); total ketone bodies in HHS were 4660.1 ± 4027.3 μmol/L, not different from DK. In the evaluation of thyroid hormone levels, FT3 was predominantly lower in DKA group, 2.17 ± 0.73 pg/mL compared to 2.76 ± 0.40 pg/mL in DK group (p<0.05). Thyroid hormone levels were not different between HHS and DK. pH and
TABLE 1 | Comparison of various values among DK, DKA and HHS group on admission.

| Parameter | DK group (n = 22) | DKA group (n=20) | p value (vs DK group) | HHS group (n=10) | p value (vs DK group) |
|-----------|------------------|------------------|----------------------|-----------------|---------------------|
| BMI (kg/m²) | 23.5 ± 5.2 | 23.9 ± 4.0 | n.s | 21.2 ± 3.7 | <0.005 |
| Body weight (kg) | 69.3 ± 11.2 | 72.4 ± 13.0 | n.s | 56.1 ± 11.8 | <0.01 |
| Age (years) | 50.3 ± 19.2 | 58.4 ± 20.2 | n.s | 70.0 ± 15.5 | <0.05 |
| Duration of diabetes (years) | 8.0 ± 8.3 | 12.7 ± 11.7 | n.s | 9.4 ± 13.3 | n.s |
| Body weight (kg) | 69.3 ± 23.3 | 56.0 ± 15.0 | <0.05 | 61.8 ± 22.0 | n.s |
| BMI (kg/m²) | 25.2 ± 6.4 | 22.0 ± 4.9 | n.s | 23.2 ± 6.6 | n.s |
| Diabetic type 1/2 | 5/17 | 1/17 | n.s | 0/10 | n.s |
| Systolic blood pressure (mmHg) | 135.9 ± 37.4 | 140.3 ± 29.8 | n.s | 135.1 ± 14.7 | n.s |
| Diastolic blood pressure (mmHg) | 87.5 ± 16.7 | 79.6 ± 25.6 | n.s | 84.9 ± 9.1 | n.s |
| Pulse rate (beats per minute) | 96.2 ± 14.1 | 107.2 ± 19.9 | n.s | 101.4 ± 27.4 | n.s |
| Body temperature (°C) | 37.0 ± 0.6 | 36.2 ± 1.6 | n.s | 36.3 ± 0.9 | <0.05 |
| Blood glucose levels (mg/dL) | 443.0 ± 161.5 | 654.7 ± 260.4 | <0.05 | 751.8 ± 146.9 | <0.005 |
| HbA1c (%), NGSP | 12.7 ± 2.5 | 12.1 ± 3.8 | n.s | 12.4 ± 3.1 | n.s |
| Glycoalbumin (%) | 36.5 ± 12.6 | 42.5 ± 11.4 | n.s | 41.8 ± 11.8 | n.s |
| Urine ketone qualitative | 2.2 ± 0.9 | 2.0 ± 1.0 | n.s | 0.8 ± 0.9 | <0.005 |
| Total ketone body (μmo/L) | 4027.3 ± 3342.9 | 10154.5 ± 5157.3 | <0.0005 | 4660.1 ± 4027.3 | n.s |
| Acetoacetic acid (μmo/L) | 1237.7 ± 1074.1 | 3145.4 ± 1717.5 | <0.0005 | 1166.7 ± 1365.1 | n.s |
| 3-Hydroxybutyric acid (μmo/L) | 2789.6 ± 2382.6 | 6965.5 ± 3594.2 | <0.0005 | 42457.7 ± 3226.1 | n.s |
| pH | 7.40 ± 0.03 | 7.19 ± 0.12 | <0.0005 | 7.36 ± 0.04 | <0.05 |
| Anion Gap | 294.1 ± 17.0 | 335.2 ± 38.2 | <0.0005 | 337.9 ± 18.7 | <0.0005 |
| Serum osmotic pressure (mOsm/kg) | 294.1 ± 17.0 | 335.2 ± 38.2 | <0.0005 | 337.9 ± 18.7 | <0.0005 |
| TSH (mU/mL) | 1.07 ± 0.58 | 1.07 ± 1.26 | n.s | 1.27 ± 0.95 | n.s |
| FT3 (pg/mL) | 2.76 ± 0.40 | 2.17 ± 0.73 | <0.05 | 2.51 ± 0.51 | n.s |
| FT4 (ng/dL) | 1.14 ± 0.19 | 1.05 ± 0.45 | n.s | 1.06 ± 0.16 | n.s |
| Total protein (g/dL) | 3.06 ± 27.2 | 38.3 ± 29.0 | n.s | 1.27 ± 20.2 | n.s |
| Creati (mg/dL) | 0.65 ± 0.22 | 2.06 ± 1.70 | <0.005 | 1.52 ± 0.74 | <0.0005 |
| Urea nitrogen (mg/dL) | 14.0 ± 6.9 | 63.0 ± 59.2 | <0.005 | 47.2 ± 28.0 | <0.0005 |
| eGFR (mL/min/1.73m²) | 102.6 ± 43.4 | 49.7 ± 40.3 | <0.0005 | 43.9 ± 22.7 | <0.005 |
| Total cholesterol (mg/dL) | 205.1 ± 58.2 | 193.3 ± 64.3 | n.s | 241.3 ± 46.6 | n.s |
| Triglyceride (mg/dL) | 195.4 ± 143.1 | 206.2 ± 64.3 | n.s | 230.7 ± 111.6 | n.s |
| LDL-cholesterol (mg/dL) | 127.2 ± 55.9 | 104.3 ± 58.3 | n.s | 131.0 ± 65.2 | n.s |
| HDL-cholesterol (mg/dL) | 43.0 ± 14.5 | 42.4 ± 19.0 | n.s | 55.1 ± 22.5 | n.s |
| UA (mg/dL) | 4.0 ± 2.18 | 13.19 ± 7.53 | <0.0005 | 7.85 ± 2.95 | <0.05 |
| CRP (mg/dL) | 2.20 ± 0.25 | 4.67 ± 6.60 | n.s | 5.49 ± 10.85 | n.s |

Data presented as mean ± standard deviation. BMI, body mass index; TSH, thyroid-stimulating hormone; FT3, free thyroxin 3; FT4, free thyroxine 4; LDL-cholesterol, low-density lipoprotein cholesterol; HDL-cholesterol, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; UA, uric acid; CRP, C-reactive protein; n.s, not significant. eGFR were lower in DKA and HHS groups compared to DK group, and Anion Gap, serum osmolality, creatinine, and urea nitrogen were higher in DKA and HHS groups.

### Changes in Thyroid Hormone Levels Before and After Treatment

Thyroid hormone levels were retested on a mean of 13.2 days after initiation of treatment for hyperglycemia-related metabolic disorders. The changes in thyroid hormone levels before and after treatment are shown in Figure 1. TSH (mU/mL) increased from 1.27 ± 1.20 to 2.56 ± 2.08 (p = 0.0029). FT3 (pg/mL) increased from 1.27 ± 1.20 to 2.56 ± 2.08 (p = 0.0026). FT4 (pg/mL) increased from 2.32 ± 0.69 to 4.63 ± 2.76 ± 0.33 (p = 0.00037). There was no significant change in FT4 between before and after treatment.

### Changes in Various Parameters With and Without NTI

The frequency of NTI was 80% in DKA group, 70% in HHS group and 50% in DK group. Thyroid function in patients without and with NTI is as follows: In patients without NTI, TSH 1.57 ± 0.72 μU/mL, FT3 2.29 ± 0.57 pg/mL, FT4 1.07 ± 0.37 ng/dL; in patients with NTI, TSH 0.94 ± 0.15 μU/mL, FT3 2.29 ± 0.57 pg/mL, FT4 1.14 ± 0.18 ng/dL. TSH and FT3 were lower in patients with NTI compared with those without NTI (p=0.0029, p=0.0015). There was no difference in FT4. Total ketone body, 3-hydroxybutyrate, uric acid and CPR were significantly higher in patients with NTI (p=0.0052, p=0.0042, p=0.024, p=0.050) (Table 2).

### Evaluation About Which Factors Independently Influence FT3 Levels

FT3 levels were negatively correlated with blood glucose levels, glycoalbumin, serum osmolality, anion gap, 3-hydroxybutyrate, creatinine, urea nitrogen, uric acid, and CRP on admission. FT3 value was positively correlated with albumin and eGFR. Next, to examine which factors independently influence FT3 levels, we performed multivariate linear regression analysis by using variables that showed significant correlations in the above analysis as explanatory variables and FT3 as an objective variable. As the results, 3-hydroxybutyrate was independently associated with FT3 (Table 3). The correlation between these variables and FT3 were as follows: eGFR was positively correlated with FT3 (p=0.0042), TSH (p=0.024), and CRP (p=0.050) (Table 3).
dependent variables and FT3 is shown in the scatter plot in Figure 2 (r = −0.48955802, p = 0.00023).

**DISCUSSION**

In this study, we focused on the effect of metabolic disorders related to hyperglycemia on thyroid hormone levels in adult patients. Previous reports of pediatric cases suggested that 3-hydroxybutyrate and albumin may contribute to the development of NTI (7, 9). In adult cases, FT3 was correlated with blood glucose level, serum osmolality, ketosis, albumin, renal function, and CRP on admission. In addition, 3-hydroxybutyrate and albumin were independently associated with FT3. In contrast to previous studies in pediatric patients, no significant correlations were found between TSH, FT4, and other parameters in adult patients. In general, serum level of each thyroid hormone changes with time after the onset of NTI, and many patients with NTI are usually treated at a relatively early stage of the disease. We assume that such background can, at least in part, explain the reason why only FT3 level was associated with various parameters in this study (2).

This is a single-center, retrospective, observational study. Patients admitted for DKA, HHS, and DK with hyperglycemia and metabolic ataxia were included and analyzed. While few studies have reported that HHS causes NTI, it is very interesting that HHS may affect thyroid function in addition to ketosis. On the other hand, since the number of HHS patients hospitalized during the study period was small, further detailed analysis with a larger number of subjects would be necessary to strengthen our hypothesis obtained in this study.

**TABLE 2 |** Comparison of various parameters in subjects with and without NTI.

| Parameter                          | with NTI (n=34) | without NTI (n=18) | p value |
|------------------------------------|----------------|--------------------|---------|
| Blood glucose levels (mg/dL)      | 584.0 ± 233.5  | 600.3 ± 274.5      | n.s     |
| HbA1c (%, NGSP)                    | 12.3 ± 3.0     | 12.9 ± 3.8         | n.s     |
| Total ketone body (µmol/L)        | 7927.0 ± 5346.7| 3655.9 ± 3840.5    | <0.05   |
| Acetoacetic acid (µmol/L)         | 2393.0 ± 1692.0| 1240.8 ± 1390.5    | <0.05   |
| 3-Hydroxybutyric acid (µmol/L)    | 5470.6 ± 3806.4| 2415.1 ± 2415.1    | <0.005  |
| TSH (µU/mL)                        | 0.94 ± 1.05    | 1.57 ± 0.72        | <0.005  |
| FT3 (pg/mL)                        | 2.29 ± 0.57    | 2.95 ± 0.31        | <0.005  |
| FT4 (mg/dL)                        | 1.07 ± 0.37    | 1.14 ± 0.18        | n.s     |
| UA (mg/dL)                         | 10.2 ± 7.0     | 6.1 ± 2.7          | <0.05   |
| CRP (mg/dL)                        | 5.31 ± 8.50    | 1.05 ± 1.36        | <0.05   |

Data presented as mean ± standard deviation. TSH, Thyroid-stimulating hormone; FT3, free thyroxin 3; FT4, free thyroxine 4; UA, uric acid; CRP, C-reactive protein; n.s, not significant.

**TABLE 3 |** Multiple regression analysis about several factors influencing FT3 levels.

| Parameter                          | Standard β  | t value | p value |
|------------------------------------|-------------|---------|---------|
| Age (years)                        | −0.135      | −0.91   | n.s     |
| Male (%)                           | 0.081       | 0.56    | n.s     |
| Blood glucose levels (mg/dL)       | −0.166      | −1.10   | n.s     |
| 3-Hydroxybutyric acid (µmol/L)     | −0.508      | −3.54   | <0.005  |
| Parameter                          | Standard β  | t value | p value |
| Age (years)                        | −0.039      | −0.31   | n.s     |
| Male (%)                           | 0.131       | 1.11    | n.s     |
| Blood glucose levels (mg/dL)       | −0.182      | −1.47   | n.s     |
| 3-Hydroxybutyric acid (µmol/L)     | −0.506      | −4.29   | <0.005  |
| CRP (mg/dL)                        | −0.444      | −3.78   | <0.005  |

CRP, C-reactive protein; n.s, not significant.
FIGURE 2 | Correlation between free thyroxine 3 (FT3) level and various parameters. Creatinine, urea nitrogen, estimated glomerular filtration rate (eGFR), albumin, and CRP were converted to natural logarithm. There was a significant negative correlation between FT3 and blood glucose levels on admission, glycoalbumin, serum osmolality, Anion Gap, 3-hydroxybutyrate, total ketones, creatinine, urea nitrogen, uric acid, and CRP. There was a significant positive correlation between FT3 and albumin and eGFR.
Since true hypothyroidism is involved in pathophysiology such as circulatory dynamics and fluid retention, it is not uncommon to struggle with the decision of replacement therapy, especially in critically ill patients. On the other hand, it has been reported that thyroid hormone replacement therapy for NTI in patients admitted to the ICU does not show beneficial effect on subsequent outcome, but rather suppresses TSH secretion and inhibits improvement of NTI (10). This study shows that NTI associated with acute metabolic disorder can be improved by treatment for primary disease in a couple of weeks without thyroid hormone replacement therapy.

To the best of our knowledge, this is the first report showing the influence of hyperglycemia-related metabolic disturbance on thyroid function in adult subjects. The data in this study clearly shows that transient NTI is frequently observed in subjects with acute metabolic disorders such as DKA, HHS and DK. In addition, we should bear in mind that thyroid hormone replacement therapy is not necessary in subjects with NTI due to DKA, HHS and DK, especially when overt symptoms of hypothyroidism are not observed.

REFERENCES

1. Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of Tri-Iodothyronine Replacement on the Metabolic and Pituitary Responses to Starvation. N Engl J Med (1979) 300(11):579–84. doi: 10.1056/NEJM197903153001102

2. Warner MH, Beckett GJ. Mechanisms Behind the Non-Thyroidal Illness Syndrome: An Update. J Endocrinol (2010) 205(1):1–13. doi: 10.1677/JEO-09-0412

3. St Germain DL, Galton VA, Hernandez A. Minireview: Defining the Roles of the Iodothyronine Deiodinases: Current Concepts and Challenges. Endocrinology (2009) 150(3):1097–107. doi: 10.1210/en.2008-1588

4. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, et al. Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling. Endocr Rev (2008) 29(7):898–938. doi: 10.1210/er.2008-0019

5. Schlienger JL, Anceau A, Chabrier G, North ML, Stephan F. Effect of Diabetic Control on the Level of Circulating Thyroid Hormones. Diabetologia (1982) 22(6):486–8. doi: 10.1007/BF00282596

6. Moura Neto A, Parisi MC, Tambascia MA, Pavin EJ, Alegre SM, Zantus-Wittmann DE. Relationship of Thyroid Hormone Levels and Cardiovascular Events in Patients With Type 2 Diabetes. Endocrine (2014) 45(1):84–91. doi: 10.1007/s12020-013-9938-6

7. Shao P, Guo S, Li G, Qin D, Li S, Luan Y. Determinants of Deranged Thyroid Function Parameters in Children Admitted for Management of Diabetic Ketoacidosis/Diabetic Ketoisis. BMC Endor Disord (2020) 20(1):135. doi: 10.1186/s12902-020-01616-2

8. Berk J, Wade R, Baser HD, Lado J. Case Report: Severe Reversible Cardiomyopathy Associated With Systemic Inflammatory Response Syndrome in the Setting of Diabetic Hypersomolar Hyperglycemic non-Ketotic Syndrome. BMC Cardiovasc Disord (2015) 15:123. doi: 10.1186/s12872-015-0112-3

9. Hu YY, Li GM, Wang W. Euthyroid Sick Syndrome in Children With Diabetic Ketoacidosis. Saudi Med J (2015) 36(2):243–7. doi: 10.15537/smj.2015.2.10304

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board of Kawasaki Medical School. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

YI researched data and wrote the manuscript. TK, FT, TS, MK, EN, KD, RW, HI, KT, JS, YF, YK, MS, SN, TM, and KK participated in discussion. HK participated in discussion and reviewed the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of Interest: HK has received honoraria for lectures, received scholarship grants, and received research grant from Novo Nordisk Pharma, Sanofi, Eli Lilly, Boehringer Ingelheim, Taiso Pharma, Sumitomo Dainippon Pharma, Takeda Pharma, Ono Pharma, Daichi Sankyo, Mitsubishi Tanabe Pharma, Kissei Pharma, MSD, AstraZeneca, Astellas, Novartis, Kowa, Abbott. KK has been an advisor to, received honoraria for lectures from, and received scholarship grants from Novo Nordisk Pharma, Sanwa Kagaku, Takeda, Taisho Pharma, MSD, Kowa, Sumitomo Dainippon Pharma, Novartis, Mitsubishi Tanabe Pharma, AstraZeneca, Boehringer Ingelheim, Chugai, Daichi Sankyo, Sanofi.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Iwamoto, Kimura, Tatsumi, Sugisaki, Kubo, Nakao, Dun, Wamata, Iwamoto, Takahashi, Sanada, Fushimi, Katakura, Shimoda, Nakamishi, Mune, Kaku and Kaneto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.